Board of Directors

Scott Carr

CEO – Phoenix Technology Group

Scott Carr is a serial entrepreneur that has built successful software, data analytic and hardware companies Mr. Carr is currently the CEO at Phoenix Technology Group, a California-based company providing the leading retinal imaging platforms for eye research and general ophthalmologic imaging. Prior to Phoenix, Mr. Carr was the CEO at Modria, a global SaaS platform for online dispute resolution, taking the company from first professional funding to the sale to Tyler Technologies (NASDAQ: TYL). Mr. Carr was previously the CEO at HarvestMark (sold to Trimble: NASDAQ: TRMB), leading the company from first professional funding to deployment of its food traceability platform with hundreds of farmers, major grocery retailers and food brands including Kroger and General Mills, and implementation on billions of units of fresh food. Prior to HarvestMark, Mr. Carr was among the founders at Digimarc (NASDAQ: DMRC), a company he helped take public, and scale to over $100M in revenue, offering anti-counterfeiting, identity document production, and geospatial imaging solutions. Prior to Digimarc Mr. Carr held positions in business development and software engineering for computer hardware and manufacturing companies. Mr. Carr holds a BSCS from Oregon State University; attended advanced executive education at Stanford University and Harvard Law School; and is the co-inventor on more than 50 patents.


Elizabeth L. R. Donley, JD, MBA, MS

Chief Executive Officer

Ms. Donley brings a unique combination of business and legal experience to Stemina. She has more than twenty years of experience in intellectual property, law, and business management. Ms. Donley served as General Counsel and Director of Business Development for Wisconsin Alumni Research Foundation (WARF) for more than eight years. During that time, Ms. Donley negotiated hundreds of licenses and sponsored research and collaboration agreements between industry and WARF, the intellectual property management organization for the University of Wisconsin.

Heiner Dreismann, Ph.D.

Former President & CEO – Roche Molecular Systems; Global Head of Business Development – Roche Diagnostics

Dr. Dreismann joined the company’s Board of Directors in August 2017. Dr. Dreismann had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO of Roche Molecular Systems, Head of Global Business Development for Roche Diagnostics and Member of Roche’s Global Diagnostic Executive Committee. Dr. Dreismann currently serves on the boards of several public and private health care companies. He earned a master of science degree in biology and his doctor of philosophy degree in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Münster) in Germany.

Andrew Ferrara

Chairman – Boston HealthCare

Mr. Ferrara began his career with Eli Lilly & Company. In the course of his twenty-year tenure with Lilly, he served in a number of business areas in the United States and Europe. During his last four years at Eli Lilly, he was Corporate Director of New Product Planning and Licensing. His line management experience included the management of pharmaceutical operations, including all aspects of marketing and sales, for both Lilly and Dista in France and a member of the Board of Lilly Industries in the United Kingdom. In May, 1984, Mr. Ferrara co-found Polygen Corporation, a computer software company serving the chemical and pharmaceutical research industries, and initiated a number of research and licensing agreements with academic institutions and major health care corporations in the United States, Europe, and Japan.

Since founding Boston Healthcare in 1993, he has been involved in the development of a number of companies. Presently he serves on the Board of Overseers of the Supreme Judicial Court and as Chair of the Board at Inform Genomics.

Kevin Krenitsky, MD

President – OpGen

With more than 15 years of experience leading and managing global diagnostic and biotechnology operations, including senior commercial and operational responsibilities at Foundation Medicine, Dr. Krenitsky recently joined OpGen as President to oversee the rollout of the company’s Acuitas® MDRO (Multi-Drug Resistant Organisms) family of Gene Tests and the Acuitas Lighthouse™ MDRO Management System, which is in development. Through December 2014, Dr. Krenitsky was chief commercial officer & SVP of International Strategy and previously chief operating officer of Foundation Medicine. He joined Foundation in  June 2011 and was instrumental in taking the company from a start-up organization to a successful IPO in 2013, followed by a major $1.2B investment by Roche making them majority stakeholders.

Prior to Foundation Medicine, he served as president of Enzo Clinical Labs, where he instituted a comprehensive strategic and operational plan that led to the introduction and launch of numerous FDA-approved esoteric tests, as well as several new laboratory developed tests. Dr. Krenitsky served as chief executive officer at both BioServe Biotechnologies, a global biotechnology company specializing in processing genetic diagnostic tests, and Parkway Clinical Laboratories, a clinical diagnostic lab providing comprehensive routine and esoteric testing. He also held various senior-level positions within Genomics Collaborative, Inc. (a SeraCare Life Sciences Company), a full-scale clinical and genomics research company. Dr. Krenitsky received a B.S. in business management from the University of Scranton and an M.D. from Jefferson Medical College (now the Sidney Kimmel Medical College) in Philadelphia. He is a former member of the Board of Directors of the New York State Clinical Lab Association and of BioServe Biotechnologies, and serves on the Board of Directors of Lumicell.


R. Andrew Morgan, R.Ph

Executive Vice President Regulatory Affairs & Quality Operations – Zurex Pharma and Zurex PharmAgra

Andrew Morgan is the Executive Vice President of Regulatory Affairs and Quality Operations for Zurex Pharma and for its Agricultural technology subsidiary Zurex PharmAgra. Prior to joining Zurex, he served as the Vice President of Quality Operations and site manager for Genzyme Corporation’s Middleton, Wisconsin office. Before joining Genzyme he served as the Vice President of Regulatory, Quality, and Pharmaceutical Sciences at Bone Care International in Middleton and held that position until the company’s acquisition by Genzyme in July 2005. Prior to joining Bone Care he was the Director of Regulatory Affairs for Celltech Pharmaceuticals, Inc. in Rochester, New York; and before joining Celltech he was the manager of regulatory affairs, labeling, and advertising compliance for Medeva Pharmaceuticals in Fort Worth Texas.

He has over 25 years of experience in the industry helping lead small pharmaceutical companies’ growth while being responsible for and having expertise in regulatory affairs, quality control, quality assurance, drug development, manufacturing, labeling and advertising, and product compliance activities. Andrew currently serves on the WARF Accelerator Program as a Pharmaceutical Catalyst and on the Technology Advisory Board for the DaneVest Tech Fund. Mr. Morgan received his Bachelor of Science of Pharmacy degree from SWOSU School of Pharmacy in Weatherford, Oklahoma and is a registered pharmacist.


Marc Schneebaum

Senior Vice President and Chief Financial Officer – Madrigal Pharmaceuticals

Mr. Schneebaum brings over 25 years of experience in the biotechnology and healthcare sector to Synta. Most recently, he has served as a consultant in the healthcare industry. From 2011 to 2013, Mr. Schneebaum served as President, Chief Executive Officer and a director of Predictive BioSciences, Inc., a commercial stage cancer diagnostics company. From 1997 to 2010, he served as President, Chief Executive Officer, and a director of Sensors for Medicine and Science, Inc., an emerging medical technology company. From 1991 to 1997, he served as Senior Vice President, Finance, Business Development and Administration, and Chief Financial Officer of Genetic Therapy, Inc., a biotechnology company (acquired by Sandoz/Novartis). From 1987 to 1991, Mr. Schneebaum was a Vice President at Alex Brown & Sons Incorporated, a leading investment banking firm (now part of Deutsche Bank), where he participated in a variety of finance and strategic assignments.

Mr. Schneebaum began his career in the accounting and auditing group at KPMG LLP, advancing to Senior Manager in the management consulting group. Mr. Schneebaum has served as a director of GenVec, Inc., a publicly traded biopharmaceutical company, since 2007. Mr. Schneebaum received his degree in Business Administration from the University of Maryland and is a Certified Public Accountant (inactive).